{"id":1305,"date":"2018-07-18T03:17:27","date_gmt":"2018-07-18T08:17:27","guid":{"rendered":"https:\/\/www.creative-biolabs.com\/blog\/?p=1305"},"modified":"2018-10-10T21:28:06","modified_gmt":"2018-10-11T02:28:06","slug":"first-approval-for-erenumab","status":"publish","type":"post","link":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/first-approval-for-erenumab\/","title":{"rendered":"First Approval for Erenumab"},"content":{"rendered":"<p><a href=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2018\/07\/erenumab.jpg\"><img decoding=\"async\" loading=\"lazy\" class=\"aligncenter size-full wp-image-1306\" src=\"https:\/\/www.creative-biolabs.com\/blog\/wp-content\/uploads\/2018\/07\/erenumab.jpg\" alt=\"erenumab\" width=\"300\" height=\"300\" \/><\/a><\/p>\n<p><span style=\"font-size:15px\">On May 17, 2018, the U.S.\u00a0Food and Drug Administration approved <a class=\"\" href=\"https:\/\/www.creativebiolabs.net\/Erenumab-67678.htm\" target=\"_blank\"><strong><span style=\"color: #3366ff;\">erenumab<\/span><\/strong><\/a>-aooe (Aimovig)<a href=\"https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm608120.htm?utm_campaign=05172018_PR_FDA%20approves%20migraine%20prevention%20treatment&amp;utm_medium=email&amp;utm_source=Eloqua\" target=\"_blank\" rel=\"noopener\">\u00a0<\/a>for the preventive treatment of migraine in adults. Erenumab is a human monoclonal antibody that targets calcitonin gene-related peptide (CGRP) receptor, thereby blocking the activity of CGRP, which is involved in migraine attacks. The treatment is given by once-monthly subcutaneous injections.<\/span><\/p>\n<p><span style=\"font-size:15px\">The approval was based on data from three clinical trials that compared erenuman-aooe to placebo. Over 2000 participants were included in the studies. In the first study (STRIVE, NCT02456740), which included 955 participants with a history of episodic migraine, patients administered erenumab-aooe experienced, on average, one to two fewer monthly migraine days than those on placebo over a 6 month period. In the second study (ARISE, NCT02483585), which included 577 patients with a history of episodic migraine, patients administered erenumab-aooe experienced, on average, one fewer migraine day per month than those on placebo over a 3 month period. The third study, which evaluated 667 patients with a history of chronic migraine, patients treated with erenumab-aooe experienced, on average, 2.5 fewer monthly migraine days than those receiving placebo over a three month period.<\/span><\/p>\n<p>&nbsp;<\/p>\n<p>Source:https:\/\/www.antibodysociety.org\/tag\/approved-antibodies\/<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On May 17, 2018, the U.S.\u00a0Food and Drug Administration approved erenumab-aooe (Aimovig)\u00a0for the preventive treatment of migraine in adults. Erenumab is a human monoclonal antibody that targets calcitonin gene-related peptide (CGRP) receptor,<a class=\"moretag\" href=\"https:\/\/www.creative-biolabs.com\/blog\/index.php\/first-approval-for-erenumab\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":1,"featured_media":1308,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[110],"tags":[70,74,62],"_links":{"self":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts\/1305"}],"collection":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/comments?post=1305"}],"version-history":[{"count":3,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts\/1305\/revisions"}],"predecessor-version":[{"id":1348,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/posts\/1305\/revisions\/1348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/media\/1308"}],"wp:attachment":[{"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/media?parent=1305"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/categories?post=1305"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.creative-biolabs.com\/blog\/index.php\/wp-json\/wp\/v2\/tags?post=1305"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}